DCF Advisers LLC Has $8.60 Million Stake in argenx SE (NASDAQ:ARGX)

DCF Advisers LLC lowered its holdings in argenx SE (NASDAQ:ARGX) by 1.0% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 20,000 shares of the company’s stock after selling 200 shares during the quarter. argenx comprises about 4.4% of DCF Advisers LLC’s investment portfolio, making the stock its 4th largest position. DCF Advisers LLC’s holdings in argenx were worth $8,601,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Wealth Alliance lifted its position in argenx by 4.8% during the 2nd quarter. Wealth Alliance now owns 628 shares of the company’s stock valued at $270,000 after purchasing an additional 29 shares during the period. Lindbrook Capital LLC raised its position in argenx by 23.1% in the 1st quarter. Lindbrook Capital LLC now owns 197 shares of the company’s stock valued at $78,000 after buying an additional 37 shares during the last quarter. Wahed Invest LLC lifted its position in shares of argenx by 9.6% in the fourth quarter. Wahed Invest LLC now owns 457 shares of the company’s stock worth $174,000 after purchasing an additional 40 shares in the last quarter. GAMMA Investing LLC lifted its position in argenx by 51.3% during the 2nd quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock worth $51,000 after buying an additional 40 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC raised its holdings in argenx by 3.1% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 1,428 shares of the company’s stock worth $543,000 after acquiring an additional 43 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analyst Upgrades and Downgrades

ARGX has been the topic of several analyst reports. Stifel Nicolaus upped their price target on shares of argenx from $485.00 to $500.00 and gave the stock a “buy” rating in a research report on Monday, June 24th. HC Wainwright upped their price objective on shares of argenx from $504.00 to $533.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Bank of America reissued a “buy” rating and set a $607.00 price target (up previously from $535.00) on shares of argenx in a report on Monday, June 24th. William Blair restated a “market perform” rating on shares of argenx in a research report on Monday, June 17th. Finally, Wells Fargo & Company boosted their price target on argenx from $543.00 to $547.00 and gave the stock an “overweight” rating in a report on Friday, July 26th. Three analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $547.74.

argenx Stock Performance

Shares of ARGX opened at $536.34 on Friday. The firm has a market cap of $31.88 billion, a PE ratio of -94.76 and a beta of 0.62. argenx SE has a 52-week low of $327.73 and a 52-week high of $554.74. The business’s 50 day moving average price is $509.76 and its two-hundred day moving average price is $430.73.

argenx (NASDAQ:ARGX) last issued its earnings results on Thursday, July 25th. The company reported $0.45 EPS for the quarter, beating the consensus estimate of ($0.89) by $1.34. argenx had a negative return on equity of 7.33% and a negative net margin of 12.31%. The company had revenue of $489.43 million during the quarter, compared to the consensus estimate of $436.66 million. During the same period last year, the business posted ($1.69) EPS. Research analysts predict that argenx SE will post -0.37 EPS for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.